Clinical trial
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
NCT01737398 · Ionis Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT01737398 |
|---|---|
| Title | Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy |
| Official title | A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (NEURO-TTR Study) |
| Lead sponsor | Ionis Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis |
| Intervention type | Drug |
| Interventions | Inotersen, Placebo |
| Enrollment | 173 |
| Start date | Mar 15, 2013 |
| Primary completion | Mar 3, 2017 |
| Completion | Nov 7, 2017 |
| First posted | Nov 29, 2012 |
| Last update posted | Jul 17, 2019 |
| Countries | Argentina, Brazil, France, Germany, Italy, New Zealand, Portugal, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: